Valuation: Impax Laboratories Inc

Market Cap 636.69Cr 554.55Cr 524.85Cr 476.86Cr 890.85Cr 61TCr 895.24Cr 6.25TCr 2.42TCr 31TCr 2.39TCr 2.34TCr 99TCr P/E 2026 *
37.3x
P/E 2027 * 22.8x
Enterprise Value 868.46Cr 756.43Cr 715.9Cr 650.45Cr 1.22TCr 83TCr 1.22TCr 8.53TCr 3.3TCr 42TCr 3.26TCr 3.19TCr 1,35300Cr EV / Sales 2026 *
2.75x
EV / Sales 2027 * 2.43x
Free-Float
44.36%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 01/08/2019
Chief Executive Officer 54 01/08/2019
Director of Finance/CFO 58 07/11/2023
Director TitleAgeSince
Director/Board Member 59 07/11/2023
Director/Board Member 70 07/11/2023
Director/Board Member 52 07/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-2.92% - - 636.69Cr
+1.28%+2.62%+51.61%+100.19% 1,02700Cr
+1.10%+1.45%+52.49%+67.37% 65TCr
+0.58%+3.54%+19.57%+73.56% 47TCr
-0.15%+5.29%+38.59%+40.49% 35TCr
+0.10%+3.89%+20.37%+26.49% 27TCr
+0.54%+7.02%+11.40%+16.80% 26TCr
+0.91%-0.70%+38.25%+45.67% 21TCr
+1.67%+2.79%-27.61%-56.31% 19TCr
+2.17%+4.20%+34.41%+99.41% 19TCr
Average -0.15%+2.49%+26.56%+45.96% 40.02TCr
Weighted average by Cap. -0.31%+2.62%+35.33%+62.18%

Financials

2026 *2027 *
Net sales 315.41Cr 274.72Cr 260Cr 236.23Cr 441.32Cr 30TCr 443.5Cr 3.1TCr 1.2TCr 15TCr 1.18TCr 1.16TCr 49TCr 343.87Cr 299.51Cr 283.46Cr 257.54Cr 481.14Cr 33TCr 483.51Cr 3.38TCr 1.31TCr 17TCr 1.29TCr 1.26TCr 54TCr
Net income 17Cr 14Cr 14Cr 12Cr 23Cr 1.58TCr 23Cr 162.41Cr 63Cr 805.06Cr 62Cr 61Cr 2.58TCr 27Cr 24Cr 23Cr 21Cr 38Cr 2.63TCr 39Cr 269.21Cr 104.1Cr 1.33TCr 103Cr 100.71Cr 4.27TCr
Net Debt 231.77Cr 201.87Cr 191.06Cr 173.59Cr 324.29Cr 22TCr 325.89Cr 2.28TCr 879.94Cr 11TCr 870.67Cr 851.29Cr 36TCr 199.52Cr 173.78Cr 164.47Cr 149.44Cr 279.17Cr 19TCr 280.55Cr 1.96TCr 757.51Cr 9.71TCr 749.53Cr 732.85Cr 31TCr
Logo Impax Laboratories Inc
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!